Multimodal Spectroscopy to Detect Urothelial Cancer in Urine
"The Feasibility of a Multimodal Spectroscopy Analysis to Detect Urothelial Cancer in Urine"
To facilitate the follow-up of urothelial tumors and also make them more tolerable and less invasive for patients, there is a minimally invasive and easy to perform examination which is urinary cytology on 3 samples. This test is extremely specific, over 90% chance of cancer if it is positive and is performed by expert cytopathologists, but it is burdened by a very low sensitivity, which is especially acute in the case of low grade tumors. This makes it an extremely useful test in case of positivity, but of little use if negative or doubtful, not being able to consider it reliable. To overcome this problem, our study aims to bring an approach based on a physical principle, that is spectroscopy, which is fast non-invasive and does not require the use of additional substances or contrast media in the diagnosis of urothelial neoplasms in samples of urine. In our experience, multimodal optical fiber spectroscopy has proved extremely valid in discriminating healthy urothelial tissue from tumor ex vivo, as well as providing important information on the degree of urothelial neoplasia, with accuracy rates higher than 80%, for which developed the idea of a technique based on multimodal spectroscopy. If our method proves valid, it could improve the follow up and management of patients with urothelial cancer, being able to support normal cytology and provide further support to the cytopathologist, as well as simplify the diagnosis.
Urine Multimodal Spectroscopy Reliability
Urine Multimodal Spectroscopy Grading
Urinary Multimodal Fiber Optic Spectroscopy
Study Arms / Comparison Groups
Patients Positive for Urinary Tract Cancer
Description: Patients will undergo urinary cytology, multimodal spectroscopy in urine and urologic surgical intervention The group of cases will consist of patients who meet the inclusion and exclusion criteria in the operative note for: Transurethral Resection of Bladder Neoplasia (TURBT) Radical Cystectomy for Bladder Neoplasia Diagnostic ureterorenoscopy and / or laser treatment of ureteral and / or renal pelvis neoplasia Segmental ureterectomy with or without ureteral reimplantation Nephroureterectomy with or without bladder cuff excission
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
January 28, 2021
January 25, 2024
Primary Completion Date
December 20, 2023
CASES Inclusion criteria Patients over the age of 18 who are known for urological interventions for the following pathologies will be considered for enrollment in the group of cases: - Bladder cancer - Urethral tumor - Renal Pelvis Tumor - Ureteral tumor The exclusion criteria will be: - Age under 18 - Pregnancy - Lack of informed consent - Persons with indwelling catheter - Presence of prostate cancer - Presence and / or history of renal cancer, except tumors of the renal pelvis CHECKS Inclusion criteria Patients over the age of 18 who are known for urological interventions for the following pathologies will be considered for enrollment in the control group: - Kidney, ureteral or bladder stones - BPH The exclusion criteria will be: - Age under 18 - Pregnancy - Lack of informed consent - Indwelling Catheter wearers - Presence of prostate cancer - Presence of kidney cancer, including kidney pelvic tumors - Presence and / or history of ureteral cancer - Presence and / or history of bladder cancer - Presence and / or history of urethral cancer
18 Years - N/A
Accepts Healthy Volunteers
Mauro Gacci, MD, 3473050852, [email protected]
University of Florence
Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy
Mauro Gacci, MD, Principal Investigator, Careggi University Hospital